Paolo Fundaro - 25 May 2022 Form 4 Insider Report for INTERCEPT PHARMACEUTICALS, INC.

Role: Director, 10%+ Owner
Signature: /s/ Rocco Venezia, as attorney-in-fact
Issuer symbol: N/A
Transactions as of: 25 May 2022
Net transactions value: $0
Form type: 4
Filing time: 27 May 2022, 16:20:35 UTC
Previous filing: 01 Jun 2021
Next filing: 25 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICPT	Common Stock	Award	$0	+7,737	+28%	$0.000000	35,794	25 May 2022	Direct	F1
holding	ICPT	Common Stock						4,000,000	25 May 2022	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICPT	Option to Purchase Common Stock	Award	$0	+12,790		$0.000000	12,790	25 May 2022	Common Stock	12,790	$16.82	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders.
F2	These shares are held by Genextra S.p.A. ("Genextra"). Mr. Fundaro is the Chief Executive Officer of Genextra. He disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any.
F3	All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders.